Plain-English translation of NCT07064759 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new treatment called 4D-150, which is a gene therapy delivered as a single injection into the eye, for adults with wet age-related macular degeneration — a condition where abnormal blood vessels grow under the retina and blur your central vision. The study compares this new medication to aflibercept, a standard treatment that requires repeated injections. Researchers hope that one injection of this treatment might work as well as or better than multiple injections of the standard drug.
Current treatments for wet age-related macular degeneration require repeated eye injections over months or years, which can be burdensome for patients. This trial is exploring whether this medication — delivered as a single injection — could provide long-lasting benefit while reducing the number of times patients need to return to the eye clinic.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll receive either the new 4D-150 injection or the standard aflibercept injection into your eye. Researchers will monitor your vision and eye health with regular imaging and eye exams over the study period to see how well the treatment works and check for any side effects. You'll be randomly assigned to one of the two treatment groups, and neither you nor the study doctors will know which treatment you received until the trial ends, ensuring a fair comparison.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States